Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTAA09 in R/R B-cell Non-Hodgkin's Lymphoma
NCT06503211Phase 1Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UTAA09 in B-cell non-Hodgkin lymphoma, sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Incidence of Dose Limiting Toxicity at 28 days and Incidence of Treatment-Emergent Adverse Events at 28 days. Started Jul 2024; status: recruiting.
02
Drugs
UTAA09
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06503211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06503211.